Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multicenter, Open-Label Study to Assess the Pharmacodynamics, Safety, and Tolerability of DT-168 Ophthalmic Solution in Patients With Fuchs Endothelial Corneal Dystrophy Undergoing Keratoplasty

NCT07024693 is registered in ClinicalTrials.gov with Design Therapeutics, Inc. as lead sponsor.

NCT NCT07024693
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07024693 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multicenter, Open-Label Study to Assess the Pharmacodynamics, Safety, and Tolerability of DT-168 Ophthalmic Solution in Patients With Fuchs Endothelial Corneal Dystrophy Undergoing Keratoplasty
Lead sponsor
Design Therapeutics, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
July 30, 2025
Completion date
December 31, 2027
Enrollment
70 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

fuchs, fuchs endothelial corneal dystrophy